Shares of Galera Therapeutics (NASDAQ:GRTX) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating.
Brokerages have set a one year consensus target price of $15.00 for the company and are expecting that the company will post ($0.45) earnings per share for the current quarter, according to Zacks. Zacks has also given Galera Therapeutics an industry rank of 55 out of 255 based on the ratings given to its competitors.
GRTX has been the subject of a number of recent analyst reports. Credit Suisse Group started coverage on shares of Galera Therapeutics in a research report on Monday. They set a “neutral” rating and a $14.00 target price on the stock. Bank of America initiated coverage on Galera Therapeutics in a research note on Monday. They set a “buy” rating and a $15.00 price target on the stock. BTIG Research assumed coverage on Galera Therapeutics in a research note on Monday. They set a “buy” rating and a $30.00 price target on the stock. Finally, Citigroup initiated coverage on Galera Therapeutics in a report on Monday. They issued a “buy” rating and a $20.00 price target on the stock.
NASDAQ:GRTX traded down $0.23 during mid-day trading on Tuesday, reaching $10.67. The stock had a trading volume of 2,317 shares, compared to its average volume of 108,557. Galera Therapeutics has a twelve month low of $11.50 and a twelve month high of $14.88.
Galera Therapeutics Company Profile
Galera Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is GC4419, a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase I clinical trial for the treatment of radiotherapy-induced esophagitis.
Further Reading: What is operating income?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.